CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (RLAY) (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...
"We are very enthusiastic to evaluate Pfizer's novel investigative selective-CDK4 inhibitor atirmociclib in combination with RLY-2608, the first mutant selective PI3Ka inhibitor," said Don Bergstrom, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback